-
Something wrong with this record ?
Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective
M. Kacer, L. Kielberger, M. Bouda, T. Reischig,
Language English Country Denmark
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
25824586
DOI
10.1111/tid.12383
Knihovny.cz E-resources
- MeSH
- Acyclovir administration & dosage analogs & derivatives economics MeSH
- Antiviral Agents administration & dosage economics MeSH
- Cytomegalovirus Infections economics prevention & control MeSH
- Cytomegalovirus drug effects MeSH
- Adult MeSH
- Ganciclovir administration & dosage analogs & derivatives economics MeSH
- Middle Aged MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Postoperative Complications economics prevention & control MeSH
- Kidney Transplantation adverse effects MeSH
- Valine administration & dosage analogs & derivatives economics MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
INTRODUCTION: Valganciclovir (vGCV) and valacyclovir (vACV) are used in cytomegalovirus (CMV) prophylaxis in renal transplant recipients. The aim of this study was to compare the economic impact of both regimens during 1-year follow-up. METHODS: A total of 117 renal transplant recipients at risk for CMV were randomized to 3-month prophylaxis either with vGCV (900 mg/day, n = 60) or vACV (8 g/day, n = 57) and their data used in a pharmacoeconomic analysis. The pharmacoeconomic evaluation involved all direct CMV-related expenses in the first year after transplantation. Sensitivity analysis was employed to examine the effects of various prices of antiviral drugs and diagnostic procedures on overall CMV-related costs. Simulation of the more expensive US healthcare perspective was performed, and a scenario involving costs of acute rejection (AR) was examined. RESULTS: Overall CMV-related costs were significantly lower in the vACV arm; median United States dollars (USD) 3473 (3108-3745) vs. USD 5810 (4409-6757; P < 0.001) per patient, respectively. Our data showed that the critical determinant of the major disparity between the prophylactic regimens was the prophylaxis price. Median cost of prophylaxis in the vACV group was USD 1729 (1527-2173) compared to USD 3968 (2683-4857) in the vGCV group (P < 0.001). In sensitivity analysis of the overall CMV-related costs, the least and the most expensive pharmacotherapy and diagnostic scenarios were used; nevertheless, the vACV arm remained markedly less expensive. Simulation considering the higher physician/nurse and hospitalization fees of the US healthcare system and the scenario including expenditure associated with AR episodes also favored vACV. CONCLUSION: VACV prophylaxis for CMV is associated with a significant 44% lower cost than vGCV at the first year after renal transplantation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024251
- 003
- CZ-PrNML
- 005
- 20250402092214.0
- 007
- ta
- 008
- 170720s2015 dk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/tid.12383 $2 doi
- 035 __
- $a (PubMed)25824586
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a dk
- 100 1_
- $a Kacer, M $u Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
- 245 10
- $a Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective / $c M. Kacer, L. Kielberger, M. Bouda, T. Reischig,
- 520 9_
- $a INTRODUCTION: Valganciclovir (vGCV) and valacyclovir (vACV) are used in cytomegalovirus (CMV) prophylaxis in renal transplant recipients. The aim of this study was to compare the economic impact of both regimens during 1-year follow-up. METHODS: A total of 117 renal transplant recipients at risk for CMV were randomized to 3-month prophylaxis either with vGCV (900 mg/day, n = 60) or vACV (8 g/day, n = 57) and their data used in a pharmacoeconomic analysis. The pharmacoeconomic evaluation involved all direct CMV-related expenses in the first year after transplantation. Sensitivity analysis was employed to examine the effects of various prices of antiviral drugs and diagnostic procedures on overall CMV-related costs. Simulation of the more expensive US healthcare perspective was performed, and a scenario involving costs of acute rejection (AR) was examined. RESULTS: Overall CMV-related costs were significantly lower in the vACV arm; median United States dollars (USD) 3473 (3108-3745) vs. USD 5810 (4409-6757; P < 0.001) per patient, respectively. Our data showed that the critical determinant of the major disparity between the prophylactic regimens was the prophylaxis price. Median cost of prophylaxis in the vACV group was USD 1729 (1527-2173) compared to USD 3968 (2683-4857) in the vGCV group (P < 0.001). In sensitivity analysis of the overall CMV-related costs, the least and the most expensive pharmacotherapy and diagnostic scenarios were used; nevertheless, the vACV arm remained markedly less expensive. Simulation considering the higher physician/nurse and hospitalization fees of the US healthcare system and the scenario including expenditure associated with AR episodes also favored vACV. CONCLUSION: VACV prophylaxis for CMV is associated with a significant 44% lower cost than vGCV at the first year after renal transplantation.
- 650 _2
- $a acyklovir $x aplikace a dávkování $x analogy a deriváty $x ekonomika $7 D000212
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antivirové látky $x aplikace a dávkování $x ekonomika $7 D000998
- 650 _2
- $a Cytomegalovirus $x účinky léků $7 D003587
- 650 _2
- $a cytomegalovirové infekce $x ekonomika $x prevence a kontrola $7 D003586
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a ganciklovir $x aplikace a dávkování $x analogy a deriváty $x ekonomika $7 D015774
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a transplantace ledvin $x škodlivé účinky $7 D016030
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pooperační komplikace $x ekonomika $x prevence a kontrola $7 D011183
- 650 _2
- $a valin $x aplikace a dávkování $x analogy a deriváty $x ekonomika $7 D014633
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kielberger, L $u Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
- 700 1_
- $a Bouda, Mirko $u Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. $7 xx0330644
- 700 1_
- $a Reischig, T $u Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
- 773 0_
- $w MED00005143 $t Transplant infectious disease $x 1399-3062 $g Roč. 17, č. 3 (2015), s. 334-41
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25824586 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20250402092210 $b ABA008
- 999 __
- $a ok $b bmc $g 1239932 $s 985164
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 17 $c 3 $d 334-41 $e 20150526 $i 1399-3062 $m Transplant infectious disease $n Transpl Infect Dis $x MED00005143
- LZP __
- $a Pubmed-20170720